NBP logo

NovaBridge Biosciences

NBP
Healthcare|Biotechnology|US
$0.91
+0.00 (+0.15%)
DCF Value
$0.11
Tangible Book / Share
$1.74
Cash / Share
$1.65
Next Earnings Report
Nov 12, 2026
EPS est. -$0.08 · Revenue est. $33.6M
Financing Filings (last 12 months)
0
No shelf registrations or offering prospectuses filed.

Upcoming Data Readouts (0)

No upcoming completion dates found in active trials.

Recent Press Releases

NovaBridge Biosciences Appoints Chuck Silberstein as Chief Financial Officer
Oct 28, 2026 · GlobeNewsWire
NovaBridge Biosciences Reports Mature Phase 1b Data at ESMO 2026 Positioning Givastomig for Registrational Development
Oct 25, 2026 · GlobeNewsWire
Visara Secures Exclusive Option for Potential Acquisition of YOL104-2 for Ocular Surface Squamous Neoplasia
Oct 20, 2026 · GlobeNewsWire
Hiteck Licenses Investigational Next-Generation NGF Eye Drop HT006.2.2 to Visara for Neurotrophic Keratitis Outside Greater China
Oct 13, 2026 · PRNewsWire
Visara Expands Ophthalmology Pipeline with Exclusive License for Investigational Nerve Growth Factor Therapy for Neurotrophic Keratitis
Oct 13, 2026 · GlobeNewsWire
NovaBridge Biosciences Announces Expanded Givastomig Safety and Efficacy Data to be Presented at the European Society for Medical Oncology 2026
Oct 8, 2026 · GlobeNewsWire
NovaBridge Appoints Martin Dewhurst to Board of Directors as an Independent Director
Sep 8, 2026 · GlobeNewsWire
NovaBridge Biosciences to Participate in September Investor Conferences
Aug 27, 2026 · GlobeNewsWire
NovaBridge Reports First Half 2026 Financial Results and Highlights Pipeline Momentum and Strategic Execution
Aug 20, 2026 · GlobeNewsWire
NovaBridge to Report First Half 2026 Financial Results and Provide a Corporate Update on Thursday, August 20, 2026
Aug 13, 2026 · GlobeNewsWire

SEC Filings (85)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Nov 5, 2026SC 13D/AActivist / 5%+ stakeDocumentIndex
Oct 28, 20266-KForeign issuer reportDocumentIndex
Oct 26, 20266-KForeign issuer reportDocumentIndex
Oct 23, 20266-KForeign issuer reportDocumentIndex
Oct 13, 20266-KForeign issuer reportDocumentIndex
Sep 8, 20266-KForeign issuer reportDocumentIndex
Sep 8, 20266-KForeign issuer reportDocumentIndex
Aug 20, 20266-KForeign issuer reportDocumentIndex
Aug 20, 20266-KForeign issuer reportDocumentIndex
Aug 17, 2026S-8Employee stock planDocumentIndex
Jul 24, 20266-KForeign issuer reportDocumentIndex
Jul 17, 20266-KForeign issuer reportDocumentIndex
Jun 29, 20266-KForeign issuer reportDocumentIndex
Jun 16, 202620-F/AAnnual report (foreign)DocumentIndex
Jun 16, 20266-KForeign issuer reportDocumentIndex
Jun 16, 20266-KForeign issuer reportDocumentIndex
Apr 22, 20266-KForeign issuer reportDocumentIndex
Apr 7, 20266-KForeign issuer reportDocumentIndex
Apr 7, 202620-FAnnual report (foreign)DocumentIndex
Mar 16, 20266-KForeign issuer reportDocumentIndex
Mar 9, 20266-KForeign issuer reportDocumentIndex
Mar 3, 20266-KForeign issuer reportDocumentIndex
Feb 25, 20266-KForeign issuer reportDocumentIndex
Feb 19, 20266-KForeign issuer reportDocumentIndex
Feb 17, 20266-KForeign issuer reportDocumentIndex
Feb 6, 20266-K/AForeign issuer reportDocumentIndex
Feb 6, 20266-KForeign issuer reportDocumentIndex
Feb 3, 2026SC 13D/AActivist / 5%+ stakeDocumentIndex
Jan 22, 20266-KForeign issuer reportDocumentIndex
Jan 22, 20266-KForeign issuer reportDocumentIndex
Jan 16, 20266-KForeign issuer reportDocumentIndex
Jan 6, 20266-KForeign issuer reportDocumentIndex
Dec 18, 20256-KForeign issuer reportDocumentIndex
Dec 10, 20256-KForeign issuer reportDocumentIndex
Dec 4, 20256-KForeign issuer reportDocumentIndex
Oct 31, 20256-KForeign issuer reportDocumentIndex
Oct 30, 20256-KForeign issuer reportDocumentIndex
Oct 30, 2025424B3Offering prospectusDocumentIndex
Oct 29, 20256-KForeign issuer reportDocumentIndex
Oct 28, 20256-KForeign issuer reportDocumentIndex